Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rezolute (RZLT)
NASDAQ:RZLT
Rezolute (RZLT) Stock Price & Analysis
385 Followers
RZLT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.72 - $6.10
Previous Close$4.17
Volume184.22K
Average Volume (3M)698.16K
Market Cap
$214.28M
Enterprise Value$136.65M
Total Cash (Recent Filing)$80.00M
Total Debt (Recent Filing)$2.37M
Price to Earnings (P/E)―
Beta-0.20
Next Earnings
Sep 12, 2024EPS Estimate
-$0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.14
Shares Outstanding40,135,147
10 Day Avg. Volume994,732
30 Day Avg. Volume698,162
Standard Deviation0.27
R-Squared0.00269
Alpha-0.00264
Financial Highlights & Ratios
Price to Book (P/B)2.24
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$9.60Price Target Upside132.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Rezolute News
PremiumStock Analysis & Ideas
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $10 (or More), Say Analysts
PremiumCompany Announcements
Rezolute Shares Updated RZ402 Data Presentation OnlinePremiumCompany Announcements
Rezolute Secures Funding Through Private Placement Deal
PremiumCompany Announcements
Rezolute Raises $60M to Fund Research and Corporate Goals
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsRezolute announced positive data from the Phase 2 trial of RZ402, showing a statistically significant reduction in central subfield thickness, a marker of DME.
Financial StabilityRezolute remains well capitalized with sufficient funds to continue operations and research into the second half of 2025.
Market PotentialThe potential launch of RZ402 could lead to a commercial market over $1.5 billion, addressing a leading cause of blindness in adults worldwide and over 1 million DME patients in the US.
Bears Say
Clinical TrialsKallikrein inhibitors have been disappointing in the clinic.
Regulatory IssuesRZ358 faces a partial clinical hold in the US, introducing uncertainty in the timeline for US market access.
Study OutcomesThere was no significant change in best corrected visual acuity during the short duration of the study.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
RZLT FAQ
What was Rezolute’s price range in the past 12 months?
Rezolute lowest stock price was $0.72 and its highest was $6.10 in the past 12 months.
What is Rezolute’s market cap?
Currently, no data Available
When is Rezolute’s upcoming earnings report date?
Rezolute’s upcoming earnings report date is Sep 12, 2024 which is in 68 days.
How were Rezolute’s earnings last quarter?
Rezolute released its earnings results on May 15, 2024. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.301 by -$0.039.
Is Rezolute overvalued?
According to Wall Street analysts Rezolute’s price is currently Undervalued.
Does Rezolute pay dividends?
Rezolute does not currently pay dividends.
What is Rezolute’s EPS estimate?
Rezolute’s EPS estimate is -$0.32.
How many shares outstanding does Rezolute have?
Rezolute has 51,385,980 shares outstanding.
What happened to Rezolute’s price movement after its last earnings report?
Rezolute reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.301. Following the earnings report the stock price went down -3.396%.
Which hedge fund is a major shareholder of Rezolute?
Among the largest hedge funds holding Rezolute’s share is Blackstone Inc.. It holds Rezolute’s shares valued at 4M.
---
Rezolute Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.60 (132.45% Upside)
$9.60 (132.45% Upside)
Insider Transactions
Bought Shares
Worth $242.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 33.4%
Last 30 Days ▲ 33.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
105.92%
12-Months-Change
Fundamentals
Return on Equity
-58.75%
Trailing 12-Months
Asset Growth
-34.62%
Trailing 12-Months
Company Description
Rezolute
Rezolute, Inc. is biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.
---
RZLT Stock 12 Month Forecast
Average Price Target
$9.60
▲(132.45% Upside)
Technical Analysis
Novo Nordisk
―
Rocket Pharmaceuticals
―
Atara Biotherapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering RZLT
1 Year
1 Year Success Rate
8/18 ratings generated profit
1 Year Average Return
+41.90%
reiterated a buy rating 2 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +41.90% per trade.
---